Literature DB >> 1500510

Development of revised quality control limits for disk diffusion susceptibility tests of selected cephem antibiotics with Haemophilus influenzae and description of a new control strain.

J H Jorgensen1, A L Barry, G V Doern, M J Ferraro, P R Murray.   

Abstract

Inconsistent quality control results in disk diffusion testing of cefaclor, cefamandole, cefonicid, and cefuroxime with Haemophilus influenzae ATCC 49247 and Haemophilus test medium (HTM) prompted a search for an alternative control strain that would provide more reliable results. A five-laboratory study was conducted to evaluate two candidate H. influenzae strains as possible alternatives to the aforementioned strain. Repetitive testing of the candidate strains and H. influenzae ATCC 49247 over several days with a total of six different lots of HTM documented consistent performance of the two candidate strains and confirmed inconsistent results for some of the antibiotics with H. influenzae ATCC 49247. In particular, certain lots of HTM failed to yield cefaclor and cefamandole zone sizes within the quality control range advocated by the National Committee for Clinical Laboratory Standards. Because of the greater consistency offered by the new strains, one was selected (now designated H. influenzae ATCC 49766) to be recommended for routine quality control testing of cefaclor, cefamandole, cefonicid, cefuroxime, and the related carbacephem loracarbef. The new control strain and zone size ranges proposed here have been approved by the National Committee for Clinical Laboratory Standards in place of the previously recommended strain and zone size limits for testing of these five cephem antibiotics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500510      PMCID: PMC265436          DOI: 10.1128/jcm.30.8.2029-2032.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Quality control limits for disk diffusion and broth microdilution susceptibility tests with Haemophilus test medium.

Authors:  G V Doern; E H Gerlach; J H Jorgensen; P R Murray; C Thornsberry; J A Washington
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Nov-Dec       Impact factor: 2.803

2.  Performance of Haemophilus Test Media prepared with 12 different lots of Mueller-Hinton agar from four manufacturers.

Authors:  A L Barry; R R Packer
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

3.  Failure to detect ampicillin-resistant, non-beta-lactamase-producing Haemophilus influenzae by standard disk susceptibility testing.

Authors:  P M Mendelman; D O Chaffin; C Clausen; T L Stull; C Needham; J D Williams; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

4.  Problems with current recommendations for susceptibility testing of Haemophilus influenzae.

Authors:  P M Mendelman; E A Wiley; T L Stull; C Clausen; D O Chaffin; O Onay
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  In vitro activities of LY163892, cefaclor, and cefuroxime.

Authors:  C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

6.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

7.  Effect of the source of Mueller-Hinton agar and resistance frequency on the detection of methicillin-resistant Staphylococcus aureus.

Authors:  J A Hindler; C B Inderlied
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

8.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

9.  Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae.

Authors:  P M Mendelman; D O Chaffin; T L Stull; C E Rubens; K D Mack; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

10.  Effect of source of Mueller-Hinton agar on detection of oxacillin resistance in Staphylococcus aureus using a screening methodology.

Authors:  J A Hindler; N L Warner
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

  10 in total
  5 in total

1.  Interpretive criteria and quality control parameters for testing susceptibility of Haemophilus influenzae to enoxacin, ofloxacin, and temafloxacin.

Authors:  A L Barry; J H Jorgensen; D J Hardy; S D Allen; C N Baker; P C Fuchs; J C McLaughlin
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

Review 2.  In vitro susceptibility testing of Haemophilus influenzae: review of new National Committee for Clinical Laboratory Standards recommendations.

Authors:  G V Doern
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

3.  Comparison of agar dilution, broth dilution, and disk diffusion testing of ampicillin against Haemophilus species by using in-house and commercially prepared media.

Authors:  P C Kohner; J E Rosenblatt; F R Cockerill
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

4.  Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid.

Authors:  A L Barry; P C Fuchs; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

5.  Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testing Haemophilus influenzae on haemophilus test medium.

Authors:  G V Doern; R N Jones; E H Gerlach; J Hindler; R St Amand
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-06       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.